Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study

Area of Science:

• Allergy and Immunology
• Dermatology
• Immunotherapy

Background:

• Sublingual immunotherapy (SLIT) is effective for airway allergies but less studied in atopic dermatitis (AD).
• Limited data exist on SLIT efficacy for patients with AD.

Purpose of the Study:

• To evaluate the effect of SLIT with house dust mite (HDM) in patients with mild-moderate AD.
• To conduct a randomized controlled study assessing SLIT's impact on AD clinical outcomes.

Main Methods:

• Enrolled 96 patients (aged 4-60) with mild-moderate AD and HDM sensitization (SCORAD 7-40).
• Administered SLIT or control treatment for 24 months, recording SCORAD, VAS, and rescue medication use.
• Assessed serum specific IgE levels at 24 months.

Main Results:

• SLIT group showed significant reductions in ΔSCORAD, VAS, and rescue medication scores from 12 months compared to controls (p < 0.05).
• No significant changes in specific IgE levels were observed in either group at 24 months.
• No severe adverse events were reported during the study.

Conclusions:

• Two years of HDM SLIT significantly improved clinical symptoms and reduced drug use in mild-moderate AD patients.
• SLIT may be a valuable therapeutic option for selected AD patients.
• Further research can explore SLIT's long-term benefits and specific patient subgroups.